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Simple Summary: Bone metastasis is a debilitating, incurable complication that occurs in breast
cancer patients with a variable period of latency after treatment of the primary tumor. The seeding
of individual cancer cells in the bone marrow from the primary tumor occurs early in disease
progression. How disseminated cancer cells are able to remain dormant in the bone marrow and then
reactivate decades later to form destructive bone lesions is not fully understood. We have used model
systems to identify bone resident cell types, and molecular mediators, that influence the survival and
fate of disseminated breast cancer cells. The identification of such cellular and molecular support
mechanisms can inform the design of new therapeutic strategies aimed at eliminating indolent cancer
cells from the bone marrow, preventing progression to overt metastases.
Abstract: Metastatic breast cancer in bone is incurable and there is an urgent need to develop new
therapeutic approaches to improve survival. Key to this is understanding the mechanisms governing
cancer cell survival and growth in bone, which involves interplay between malignant and accessory
cell types. Here, we performed a cellular and molecular comparison of the bone microenvironment in
mouse models representing either metastatic indolence or growth, to identify mechanisms regulating
cancer cell survival and fate. In vivo, we show that regardless of their fate, breast cancer cells in bone
occupy niches rich in osteoblastic cells. As the number of osteoblasts in bone declines, so does the
ability to sustain large numbers of breast cancer cells and support metastatic outgrowth. In vitro,
osteoblasts protected breast cancer cells from death induced by cell stress and signaling via gap
junctions was found to provide important juxtacrine protective mechanisms between osteoblasts
and both MDA-MB-231 (TNBC) and MCF7 (ER+) breast cancer cells. Combined with mathematical
modelling, these findings indicate that the fate of DTCs is not controlled through the association
with specific vessel subtypes. Instead, numbers of osteoblasts dictate availability of protective niches
which breast cancer cells can colonize prior to stimulation of metastatic outgrowth.
Keywords: skeletal; metastasis; dormancy; latency; breast cancer
1. Introduction
The spread of cancer cells to the bone marrow occurs frequently during breast cancer
progression [1,2] and significantly increases the risk of skeletal recurrence [2]. However,
only a proportion of patients with tumor cells in their bone marrow will subsequently de-
velop clinically overt metastases, often following a prolonged period of disease latency [1,2].
The mechanisms that influence the survival and fate of disseminated tumor cells (DTCs) in
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bone during this period of metastatic dormancy are not fully understood but remain an
attractive therapeutic target.
Following their dissemination to bone, tumor cells are proposed to reside in hematopoi-
etic stem cell (HSC) niches located in proximity to blood vessels (perivascular), bone
surfaces (endosteal) or both (overlapping) [3–5]. Therefore, the fate of DTCs in bone is
likely influenced by their interactions with the cell types that co-exist in these niches.
The microvasculature in bone is complex and plays an important part in the homeostatic
regulation of the HSC pool, including control of their egress into the blood stream and
subsequent re-entry into bone marrow niches [6]. Circulating tumor cells (CTCs) are
proposed to hijack such HSC homeostatic processes, thereby gaining entry to the bone
microenvironment [3] and the perivascular niche has also been implicated as an important
regulator of metastatic dormancy in bone [7–9]. Broadly, the bone microvasculature can
be divided into two functionally distinct vessel subtypes. Blood vessels that co-express
high levels of the vascular markers CD31 and endomucin (termed type-H vessels) are more
proliferative than those that express low or undetectable levels of CD31 (termed type-L
vessels). Forming an important functional link between blood vessel and bone formation,
H-typeCD31pos vessels have a transcriptional profile enriched for osteogenic growth factors
and can regulate the expansion and differentiation of bone forming cells [10]. Osteoblasts,
derived from mesenchymal stromal/stem cells (MSCs), are the key cell type responsible
for bone formation. During their differentiation in bone, these cells can reside in both
perivascular and endosteal niches, where they regulate HSC activity [11,12]. Consequently,
osteoblastic cells are implicated as one of the key accessory cell types to DTCs during
the early stages of tumor cell colonization of bone [13]. However, the specific roles of
osteoblastic cells and different types of vessels in controlling the survival of DTCs in bone
during metastatic dormancy and outgrowth are not fully understood.
The metastatic cascade is highly inefficient, with the majority of malignant cells (>90%)
unable to survive the stresses associated with the multistep metastatic process [14–16].
Successful colonization of metastatic sites likely relies on DTCs locating to appropriate
niches, with the recruitment of accessory cell types to support their long-term survival.
The aim of this study was to identify cellular and molecular mechanisms that regulate
the fate of DTCs in bone by comparing the bone microenvironment from models with
opposing effects on the fate of DTCs, one driving outgrowth and the other promoting
indolence. Using this approach, we determined that DTCs reside in microanatomical
niches populated by osteoblastic cells. As the abundance of osteoblastic cells declines in
our indolence-inducing mouse models, so does the ability of the bone microenvironment
to sustain large numbers of DTCs. Using in vitro co-culture assays, we demonstrated that
osteoblasts deploy both paracrine and juxtacrine signals that increase tumor cell resistance
to metastasis-induced cell stress and death. We propose that osteoblasts provide a limited
number of niches capable of supporting the long-term survival of DTCs in bone and that
the innate ability to grow and form metastases is restricted to a small percentage of DTC
clones. By limiting the numbers of sites for colonization by DTCs, osteoblasts indirectly
limit the likelihood of metastatic outgrowth.
2. Results
2.1. Disseminated Breast Cancer Cells Occupy Distinct Micro-Anatomical Niches during
Metastatic Dormancy Compared to Outgrowth
To determine how the bone microenvironment influences the survival and fate of
DTCs, we used two mouse models that differ in their ability to support cancer cell growth
following their arrival in bone after intra-cardiac injection [17,18]. In the first model (6-week-
old, skeleton still developing), cancer cells rapidly grow to form overt bone metastases.
In the second model (12-week-old, mature skeleton with lower bone turnover), cancer
cells remain indolent for an extensive period of time until reactivated [17]. Regardless of
molecular subtype, our group has previously demonstrated that breast cancer cells labelled
with fluorescent, lipophilic membrane dyes preferentially colonize the metaphyseal bone
compartment in mouse models [19]. To determine whether the distribution of DTCs
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(MDA-MB-231) in this bone region might influence their fate, we mapped their distance
relative to the growth plate, a readily identifiable anatomical feature, shortly after long
bone colonization in the mouse models of outgrowth and indolence. This was carried out
via a more precise method using the immunofluorescent detection of endogenous tumor
cell antigens (CD29 and CD59), which unlike lipophilic membranes dyes, is not subject to
lateral dye transfer. In both models, DTCs were detected in niches located within 200 µm
from the growth plate (Figure 1a,b), demonstrating that the differential fate of DTCs cannot
be explained by macroscopic differences in their distribution. However, in the indolent
model there was a statistically significant micro-anatomical shift in tumor cell distribution,
with DTCs located significantly closer to the growth plate compared with the outgrowth
model (Figure 1c).
 
Figure 1. DTCs occupy distinct micro-anatomical niches in bone during metastatic indolence and out-
growth. (a) Illustrative immunofluorescent image of the metastatic region of mouse tibial metaphysis.
The growth plate is indicated by yellow dashed line and the endomucin expressing microvasculature
in green. (b) Representative images of MDA-MB-231 DTCs in tibial cryo-sections taken from the
outgrowth and indolence mouse models, acquired 6 days post-injection. Inset panel shows high
power image of individual tumor cells (in red). (c) Quantitative mapping of DTC distance to the
growth plate in outgrowth and indolence models. (d) Representative images of MDA-MB-231 DTCs
(in red) residing in perivascular (in green) and endosteal (in white) niches, in vivo. (e) Graphical
summary and comparison of DTC distribution between perivascular and endosteal niches in the
outgrowth and indolence mouse models. (OutG. = Outgrowth, Indol. = Indolence; ˆ sig. dif. w.r.t.
outgrowth (p < 0.0001); n = 5 mice/tibia per condition).
The perivascular and endosteal niches are strongly implicated in the regulation of HSC
proliferation and dormancy [12,20–24], and there is compelling evidence that DTCs hijack
HSC niches in bone [3–5,9]. We hypothesized that the shift in DTC location observed in the
indolence model could reflect either a reconfiguring of these niches, or transition of DTCs
between them. To investigate this, we established the extent to which DTCs associated
only with either the perivascular niche (using the vascular marker endomucin) [10], the
endosteal niche (using the surrogate bone marker osteopontin) [25], or with both. In
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both outgrowth and indolent models, ~50–60% of the DTCs were associated with an
overlapping niche that expressed both perivascular and endosteal markers (Figure 1d).
Importantly, there was a degree of redistribution of DTCs between different locations in
the two models. In the indolent model, there was a statistically significant reduction in the
proportion of DTCs associated with only the perivascular niche (16.1% ± 4.1), compared
with the outgrowth model (33.4% ± 5.0; p < 0.01). There was a corresponding increase
in DTC association with only the endosteal niche (dormancy 18.3% vs. outgrowth 10.0%;
p < 0.05). These data reveal a micro-anatomical repositioning of a proportion of DTCs in
bone, between the perivascular and endosteal niches during the transition from metastatic
indolence to outgrowth in vivo. Our results demonstrate that changes in both perivascular
and endosteal niches may affect the growth or survival of DTCs in bone.
2.2. The Fate of DTCs in Bone Is Not Determined by Their Interaction with Specific
Vessel Subtypes
We next investigated how the repositioning of DTCs between the perivascular and
endosteal niches in bone might influence their survival and ability to form overt metastatic
lesions. We and others have previously reported a decline in the abundance of type-
HCD31pos blood vessels in mature mice [10,26]. Thus, if CD31pos endothelial cells (ECs)
provide proliferative cues to DTCs, a reduction in this EC population could explain the
absence of metastatic outgrowth in our model of indolence. To explore this possibility,
we quantified DTC association with either type-HCD31pos or type-LCD31neg vessels in the
two models. In the outgrowth model, perivascular DTCs showed a statistically significant
bias towards type-H blood vessels (Figure 2a,b). In the indolence model, DTCs showed
no bias with an equivalent association with either vessel type (Figure 2a,b). These data
were consistent with type-HCD31pos ECs supporting the proliferation of DTCs. To validate
these findings, we used a mouse model in which indolent DTCs in the bone marrow of
mature mice are triggered to form overt metastatic lesions following ovariectomy, but not
following a sham operation [17]. However, in ovariectomized mice (outgrowth model),
perivascular DTCs showed a statistically significant bias towards type-L blood vessels,
which was also present in the sham-operated mice (indolence model) (Figure 2c,d). Taken
together, these data indicate that the fate of DTCs is not determined by the type of vessel
with which they are associated, since outgrowth occurs spontaneously in young mice when
DTCs are associated with type-HCD31pos vessels and in ovariectomized mature mice whilst
associated with type-LCD31neg vessels.
2.3. Osteoprogenitors Are Potential Accessory Cells for DTCs
Osteoprogenitors are found in both perivascular and endosteal niches in bone and may
be involved in regulating DTC survival and proliferation/dormancy. Derived from MSCs,
osteoprogenitors are the precursors of bone synthesizing osteoblasts and can be identified
by their expression of the osteogenic transcription factor ”Osterix” [10]. We quantified
the numbers of osteoprogenitors in the metaphyses of hind limbs from the indolence
and outgrowth models. Consistent with previously published data [26], osteoprogenitor
numbers were significantly reduced in the indolence model (Figure 3a). Interestingly, the
reduced abundance of osteoprogenitors was associated with a reduced ability of the bone
microenvironment to support high numbers of DTCs, a 65% decrease compared with the
outgrowth model (Figure 3b). We hypothesized that osteoprogenitors may be a source
of important survival/proliferative cues for DTCs. To test this hypothesis, we quantified
the numbers of osteoprogenitors in close proximity to DTCs in the two models. Despite
the overall decline in the abundance of osteoprogenitors in the bones of the indolence
model (mature mice), DTCs still appeared to reside in micro-anatomical niches containing
equivalent numbers of osteoprogenitors in both models (Figure 3c). These data suggest
that osteoprogenitors could be an accessory cell that promotes the survival of DTCs in
bone, but do not directly affect their ability to remain indolent.
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Figure 2. The fate of DTCs in bone is not determined by their association with osteogenic vascular
endothelium. Representative immunofluorescent images (a) and quantification (b) of MDA-MB-231
DTCs (in red) associated with CD31pos type-H (in white) and CD31neg type-L (in green) microvas-
culature in the bones of 6-week old (Outgrowth model) and 12-week old (Indolence model) mice.
Representative images (c) and quantification (d) of MDA-MB-231 DTCs associated with CD31pos
type-H and CD31neg type-L microvasculature in the bones of ovariectomised 12-week old mice (Out-
growth) and sham-operated 12-week old mice (Indolence). (OutG. = Outgrowth, Indol. = Indolence;
ˆ sig. dif. w.r.t. CD31+ (p < 0.01), § sig. dif. w.r.t. Outgrowth (p < 0.01); n = 3 mice/tibia per condition).
To test the hypothesis that the decline in the number of DTCs in the bones of mature
mice at these very early stages after colonization is sufficient to explain the observed
metastatic latency, we calculated an expression for the probability of outgrowth, P(tumor),
as a function of the number, n, of DTCs that were initially observed in bone niches (see
methods and Figure S2 for details). Our expression has the form P(tumor) = 1 − An, where
A is the ratio of the death rate to the proliferation rate of the DTCs after colonization. As
we do not have an experimental measurement of these rates, we obtained a value for this
parameter by fitting to the established outgrowth data for our mouse models [17]. Initially,
we made the assumption that all observed DTCs in both models have the same potential to
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proliferate and therefore A is equivalent for all DTCs. Our results give a value of A close to
1 i.e., the proliferation rate is only slightly larger than the death rate (Figure 3d). For the
case where A ≥ 1, all DTCs eventually die, irrespective of the initial number surviving in
bone, which is not seen in our models [17]. However, Kang et al., (2003) [27] and Lu et al.,
(2011) [28], demonstrated that the ability of MDA-MB-231 cells to grow and form overt
metastases in the bones of mice was an intrinsic property restricted to only a subset of TCs
(~11%). Therefore, we amended our mathematical model so that only 11% of the DTCs
were able to proliferate, this resulted in a fit of A = 0.885 (Figure 3d). Using this 11%, the
proliferative DTC subpopulation more clearly shows the stochastic effect of small numbers
of DTCs, since the fate of each metastatic focus is largely dependent on the initial number of
cells surviving after colonization. Based on these assumptions, our calculations suggest that
the difference in the number of surviving DTCs in the bones of our two mouse models, is a
significant factor in determining their subsequent fate, which is likely influenced directly
by the bone microenvironment. However, as can be seen from our graphical data, the
theoretical curves do not fully reproduce the observed difference in DTC fate. This suggests
the likelihood of additional cellular and molecular interactions within the surrounding
bone microenvironment having a minor influence on the death/proliferation rates of DTCs.
 
γ
Figure 3. DTCs reside in bone microenvironments rich in osterix-expressing osteoblastic cells in
both metastatic outgrowth and indolence models. (a) Representative immunofluorescent images and
quantification of Osterix+ osteoblastic cells (in red) in tibias taken from the outgrowth and indolence
Cancers 2021, 13, 1366 7 of 19
models (vasculature shown in green). (b) Representative immunofluorescent images and quantifica-
tion of DTC abundance (in red) in outgrowth and indolence models. (c) Representative images of
DTCs (in red) residing in micro-anatomical niches containing osterix+ osteoblastic cells (in white) and
quantification of osterix+ osteoblastic cells in FOV containing DTCs “hotspots”. (d) Mathematical
calculation of the probability of developing tumor growth if all DTCs have an equal likelihood of
death vs. proliferation (Model 1) and if proliferation is restricted to a subpopulation (11%) of DTCs
(Model 2). Horizontal error bars are standard error of the mean and vertical error bars are based on
the accuracy of published data. (OutG. = Outgrowth, Indol. = Indolence; ˆ sig. dif. w.r.t. outgrowth
(p < 0.05), N.S. = not significant; n = 5 mice per condition; scale bar = 100 µm).
2.4. Osteoblast-Derived Paracrine Signals Protect Breast Cancer Cells from Oxidative Stress
To investigate potential mechanisms whereby osteoprogenitors may influence the
survival of DTCs, we established a co-culture assay where MDA-MB-231 breast cancer cells
(BCCs) were cultured in the presence of murine MC3T3-E1 pre-osteoblastic cells (pre-Obs).
Co-cultures were then analyzed by flow cytometry using the expression of GFP and the cell
surface antigens CD29 and CD59 to discriminate between BCCs (GFP+CD29/CD59+) and
pre-Obs (GFPnegCD29/CD59neg). Co-culture of pre-Obs with BCCs did not significantly
alter the viability of either cell type, compared to monocultures under full (10%) serum
conditions (data not shown). We hypothesized that osteoprogenitors might protect DTCs
from the stress they encountered during the various steps of the metastatic cascade [29–32],
thereby supporting their survival. To test this, co-cultures were performed in the presence
of hydrogen peroxide (H2O2) to simulate oxidative stress. The presence of pre-Obs pro-
vided BCCs with significant protection against oxidative stress, reducing the proportion of
dead/dying BCCs (Figure 4a). The same protective effect was observed when BCCs were
co-cultured with mature osteoblasts under oxidative stress, supporting that this response
is independent of osteoblast differentiation status (Figure 4b). To determine whether this
protective effect was mediated by paracrine or juxtacrine signals, we repeated the oxidative
stress assay with BCCs cultured either alone or in medium conditioned by pre-Ob (CM).
Surprisingly, the pre-Ob CM did not protect BCCs against oxidative stress, but significantly
increased the proportion of dead/dying BCCs (Figure 4c). These data indicate that the
protective effect observed in co-culture experiments must be mediated either through
cell-cell contact or by a soluble mediator generated only during co-culture. To explore
this, we repeated the oxidative stress assay, culturing BCCs alone or in the presence of
medium pre-conditioned by a co-culture of BCCs and pre-Obs (CoCM). Interestingly, this
CoCM still provided significant protection of BCCs from the cytotoxic effects of H2O2
(Figure 4d), confirming that the protective factor was a paracrine mediator produced as
a result of cross-talk between the two cell types. As the protective effect was maintained
following heat inactivation of the CoCM, (CoCMHI) (Figure 4e), we concluded that the
paracrine protective factor was a low molecular weight, non-protein, mediator. One poten-
tial candidate molecule is glutathione, a small tripeptide that functions as an anti-oxidant
in many organisms [33]. We therefore generated glutathione-depleted CoCM by addi-
tion of buthioinine sulfoximine (BSO), a non-reversible inhibitor of γ-glutamylcysteine
synthase (the rate-limiting enzyme of the glutathione biosynthetic pathway) [34]. The
glutathione-depleted CoCM still provided significant BCC protection against oxidative
stress (Figure 4f), excluding glutathione as a protective factor. Although further work is
required to identify the low molecular weight anti-oxidant acting as the paracrine protec-
tive factor, the results demonstrate that cells of the osteoblast lineage have the capacity
to support survival of breast cancer cells undergoing stress. Interestingly, the paracrine
protective mechanism induced by cross-talk between osteoblasts and TCs appears to be
restricted to the TNBC subtype, as CoCM generated from either MDA-MB-231 (TNBC) or
MCF7 (ER+) cells, which can also form bone metastases in mice, did not protect MCF7 cells
from the cytotoxic effects of H2O2 (Figure 4g–h).
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Figure 4. Paracrine cross talk with osteoblasts protects hormone receptor negative BCCs from
oxidative stress-induced cell death. Flow cytometric quantification of tumor cell viability in ox-
idative stress assays performed using MDA-MB-231 BCCs in the presence of (a) pre-osteoblasts,
(b) mature osteoblasts (c) pre-osteoblast conditioned medium, (d) pre-osteoblast and MDA-MB-
231 co-conditioned medium, (e) heat-inactivated co-conditioned medium, (f) glutathione-depleted
co-conditioned medium. Oxidative stress assays performed using MCF7 BCCs in the presence of
(g) pre-Ob and MDA-MB-231 co-conditioned medium and (h) pre-Ob and MCF7 co-conditioned
medium. (CM = conditioned medium, CoCM = pre-Ob and BCC co-conditioned medium, HI-CoCM
= heat-inactivated pre-Ob and BCC co-conditioned medium, CoCM(231) = co-conditioned medium
from MDA-MB-231, CoCM(MCF7) = co-conditioned medium from MCF7, M-Ob = mature osteoblasts;
ˆ sig. dif. w.r.t. untreated BCCs (p < 0.0001), § sig. dif. w.r.t. BCCs + H2O2 (p < 0.01); n = 4).
2.5. Osteoblast-Derived Juxtacrine Signaling Protects Breast Cancer Cells from Cell Stress
The growth factor and cytokine milieu of the various metastatic organs is often
markedly different from one another and the primary tumor, DTCs arriving at such sites
may be exposed to stresses associated with growth factor deprivation. To mimic this
process, we established a co-culture assay in which BCCs underwent serum-starvation for
48 h in the presence of pre-Obs or mature Obs, and their viability was quantified by flow
cytometry as described in the Materials and Methods. Similar to oxidative stress, the pres-
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ence of pre-Obs had a significant protective effect on BCCs exposed to serum-deprivation
(Figure 5a). The same effect was observed when using mature osteoblasts (Figure 5b).
The protective effect could not be recapitulated using either CM or CoCM (Figure 5c,d),
suggesting that the protection is conveyed via a juxtacrine (contact-dependent) mecha-
nism. This juxtacrine protective effect of pre-osteoblasts was also observed when using
ER+ MCF7 cells, which suggested a common mechanism (Figure 5e). Integrins (αv and
β1) and notch-mediated juxtacrine signaling in bone is known to control the prolifera-
tion of DTCs [7,35–37]. Therefore, we investigated whether either of these pathways was
responsible for the protective activity of pre-Obs under serum-starvation. Neutralizing
antibodies against αv and β1 integrins, or the γ-secretase inhibitor ‘DAPT’, did not reverse
the protective effect, ruling out a role for these molecules in supporting DTC survival under
stress (Figure S3).
 
Figure 5. Osteoblast-derived juxtacrine signals protect hormone receptor positive and negative
BCCs from serum-deprivation induced cell death. Flow cytometric quantification MDA-MB-231
viability in serum-starvation assays performed in the presence of (a) pre-osteoblastic cells, (b) mature
osteoblasts (c) pre-Ob conditioned medium, (d) pre-Ob and MDA-MB-231 co-conditioned medium.
(e) Quantification of MCF7 viability in serum-starvation assays performed in the presence of pre-Ob.
(w/o FCS = without FCS, M-Ob = mature osteoblasts; ˆ sig. dif. w.r.t. BCCs in full serum (p < 0.001),
§ sig. dif. w.r.t. BCC without serum (p < 0.001); n = 4 per condition).
We hypothesized that the formation of gap junction complexes allows pre-Obs and
BCCs to share protective mediators, thereby shielding both cell-types from the cytotoxic
effects of serum-starvation. To confirm that gap junctions were forming between pre-Obs
and BCCs, we loaded pre-Obs with calcein-AM and co-cultured them with MDA-MB-231
cells for 24 h. Using confocal microscopy, we observed evidence of calcein transfer from
pre-Obs to MDA-MB-231, thereby demonstrating the formation of functional gap junction
complexes between these two cell types (Figure 6a).
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Figure 6. Gap junction signaling with osteoblasts protects BCCs from serum deprivation-induced
cell death. (a) Representative images of gap junctional-mediated calcein transfer from labeled pre-Ob
to MDA-MB-231 cells, in vitro. Flow cytometric quantification of (b) MDA-MB-231 and (c) MCF7
under serum-free conditions in the presence of pre-Ob and the gap junction inhibitor carbenoxolone
or vehicle. (CBX = Carbenoxolone, w/o FCS = without FCS; scale bar = 50 µm; ˆ sig. dif. w.r.t. BCCs
under full serum (p < 0.0001), § sig. dif. w.r.t. BCCs under serum-free conditions (p < 0.001), + sig. dif.
w.r.t. vehicle (p < 0.001); n = 4).
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We then repeated the serum-starvation assays in the presence of the gap junction
inhibitor Carbenoxolone (CBX). Preventing gap junction formation with CBX significantly
reversed the protective effect exerted by pre-Obs on both TNBC and ERpos BCCs exposed
to serum starvation (Figure 6b,c). These experiments are direct evidence that the exchange
of material through gap junctions is essential for the survival of cancer cells exposed to cell
stress, supporting a role for pre-OBs in the bone metastatic niche.
2.6. Candidate Growth Factors, Cytokines or Angiogenic Mediator Expression Does Not Explain
Differences in the Fate of DTCs
In order to identify potential mechanisms involved in regulating DTC indolence/
outgrowth, we carried out a transcriptomic and proteomic comparison of the bone microen-
vironment in the two models. Quantitative real-time PCR was used to measure the expres-
sion of 48 candidate metastasis and bone biology-related genes (Table S1) and levels of 108
different growth factors, cytokines and angiogenic mediators compared by protein array. In
the indolence model we found biologically relevant increases in the expression of five genes
compared with the outgrowth model, Spp1 (Osteopontin), Tnc (Tenascin-C), Postn (Periostin)
and Tnfsf11 (Rankl) and Tnfrsf11b (Osteoprotegerin) (Figure S1A). Of these, Spp1 and Tnfrsf11b
have been linked to metastatic dormancy [38,39] whereas Tnc, Postn and Tnfsf11, paradoxi-
cally, have been implicated as drivers of outgrowth, not dormancy/indolence [9,17].
The protein array revealed a semi-quantitative increase in the expression of five
proteins; Cxcl4, FasL, Cxcl11, Cxcl15 and Tnfrsf11b, in the indolence compared with
the outgrowth model (Figure S1B). As there is no Cxcl15 orthologue in humans, this
molecule was not pursued. To further explore whether these mediators may have a role
in determining the fate of DTCs, we examined the expression of their receptors on MDA-
MB-231 cells, in vitro. Despite absent/low cell surface expression, all receptors could
be detected as an intra-cellular pool, suggesting that MDA-MB-231 cells have the ability
to respond to these cytokines following receptor shuttling to the cell surface (data not
shown). We further validated the results of the protein array by quantifying Cxcl4, Cxcl11,
FasL and Tnfrsf11b expression by ELISA, in bone marrow protein lysates prepared from
the indolence and outgrowth models. In the indolence model there was a statistically
significant increase in the expression of Cxcl4, Tnfsf11b, but not Cxcl11 or FasL, compared
to the outgrowth model (Figure S1C). The high level of basal Cxcl4 expression in the
outgrowth model, combined with the incremental increase found in the indolence model,
suggests that this cytokine is unlikely to act as the molecular switch controlling metastatic
latency in bone. However, the elevated expression of Tnfrsf11b in the indolence model
implicates suppressed bone turnover as an important negative regulator of metastatic
outgrowth in our models.
3. Discussion
The current study presents novel data demonstrating that following initial bone
colonization, DTCs survive in micro-anatomical niches that contain an abundance of
osteoblastic cells. We also show that the ability of the bone microenvironment to support
large numbers of DTCs declines when the number of osteoblastic cells is reduced during
skeletal maturation. Furthermore, we show that both paracrine and juxtacrine signaling
with osteoblasts protects breast cancer cells from stress-induced death. Of particular
interest, heterotypic gap junction signaling with osteoblasts was found to protect both
TNBC and ERpos subtypes of breast cancer from stress induced by serum deprivation and
may, therefore, represent a common mechanism promoting the survival of breast cancer
cells in bone.
Our analysis revealed a decline in osteoblastic cells in the metaphyseal compartment
of long bones in the indolence model (mature mice, low bone turnover) compared with the
outgrowth model (young mice, high bone turnover). These observations were consistent
with previously published studies describing the age-related decline in osteoblastic cells
in mice [10,26]. If these cells provide important proliferative cues to DTCs in bone, their
decline in mature mice could explain the absence of DTC outgrowth in this model. Inter-
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estingly, we found that DTCs in both outgrowth and indolence models occupied niches
that contained equivalent numbers of osteoblastic cells, demonstrating that DTCs survived
predominantly in osteoblast-rich bone niches. The adult human skeleton contains low
numbers of osteoblastic cells that are distributed throughout the skeleton at sites of active
bone turnover, which occurs at a much slower rate than during adolescence [40,41]. If
breast cancer cells arriving in human bone need osteoblastic cells to survive, this might
partly explain the inefficiency of the metastatic process and the diffuse multi-focal pattern
of skeletal metastases observed in patients. The abundance of bone resorbing osteoclasts
also declines with age in our mouse models, we and others have already established the
important role these cells play in supporting metastatic outgrowth in bone [17,28], hence
osteoclasts were not the focus of the current study.
Taken together, these data suggested that the interaction with osteoblastic cells in bone
may provide important survival cues for MDA-MB-231 cells (TNBC), though may not influ-
ence their subsequent fate, i.e., to proliferate or not. The observation that osteoblastic cells
constitute part of the metastatic niche in bone has been reported previously [5,13,36,42–45].
The formation of heterotypic adherens junctions with N-cadherinpos osteoblasts provides
an important proliferative cue to E-cadherinpos ERpos breast cancer cells (MCF7), promoting
their growth to form overt metastases in bone [5]. However, the role of such interactions
in promoting breast cancer cell survival and resistance to stress has not previously been
investigated, nor is this mitogenic interaction applicable to all breast cancer subtypes
e.g., TNBC [5].
Gap junctions are intercellular membrane channels that permit the exchange of small
molecules, ions and metabolites between adjacent cells. They are usually formed between
cells of the same type (homotypic) via the interaction of two hexameric hemi-channels
called connexons (one hemi-channel on each cell), which in humans can be constructed from
any one of 20 connexin proteins. There is also evidence that heterotypic gap junctions can
form between breast cancer cells and osteoblasts [36,46]. Recent elegant studies by Wang
and colleagues (2018) demonstrated that the formation of heterotypic gap junctions with
osteoblasts conferred a proliferative advantage on ERpos breast cancer cells in bone, driving
tumor growth and the formation of overt metastases [13]. Similar proliferative interactions
exist between breast and lung cancer cells that metastasize to the brain, where they form
heterotypic gap junctions with astrocytes [47]. However, the role of such interactions in
supporting the survival of different subtypes of breast cancer cell in bone in the early
stages following dissemination, rather than stimulating proliferation and growth to form
tumors, was not addressed. In the present study, we have expanded on these important
findings by demonstrating that the formation of gap junctions between osteoblasts and
either MDA-MB-231 (TNBC) or MCF7 (ERpos) breast cancer cells conveyed significant
protection against stress-induced cell death triggers of the types encountered along the
metastatic cascade. To our knowledge, this is the first demonstration that heterotypic gap
junction signaling may function at an early stage after the initial arrival of cancer cells in
bone, by providing DTCs with an enhanced ability to survive the stresses associated with
the metastatic process.
We also demonstrated that paracrine signaling can protect breast cancer cells from
stress-induced cell death. Our data revealed that cross-talk between osteoblastic cells and
MDA-MB-231 (TNBC) cells resulted in the production of an as yet unidentified soluble,
thermally-resistant mediator(s), possibly an active metabolite, that conveyed significant
protection against oxidative stress. These paracrine factors were not released by osteoblasts
cultured in isolation and were not induced by co-culture with MCF7 (ERpos) breast cancer
cells. These data indicate that whilst there are common mechanisms by which these two
cell lines, representing different subtypes of breast cancer, resist stress-induced cell death
(i.e., through formation of heterotypic gap junctions), there are other as yet unidentified
processes that might be specific to both the breast cancer subtype and the type of stress
encountered. Our observation that the protective mechanisms required either direct physi-
cal contact between breast cancer cells and osteoblastic cells or an ability to communicate
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with one another, highlights the importance of using a co-culture approach, rather than
monoculture-conditioned medium assays, for characterizing such protective processes,
in vitro.
Our data demonstrate that stress-specific mechanisms of resistance to cell death are de-
ployed by BCCs and osteoblasts, however not every resistance mechanism is possessed by
each BCC subtype. MDA-MB-231 cells (TNBC) were able to elicit the support of osteoblasts
and thereby resist cell death induced by both oxidative stress (paracrine mechanism) and
growth factor deprivation (juxtacrine mechanism). In a translational setting, we would
speculate that possessing multiple mechanisms of stress resistance would make TNBC
bone metastases more difficult to treat than ERpos metastases. We found that gap junctional
signaling between MDA-MB-231 tumor cells and osteoblasts was important in protecting
against growth factor deprivation. However, it is not clear if targeting this support mecha-
nism alone would have efficacy in cancer patients. Additional work is required to identify
the paracrine mechanisms mediating resistance to oxidative stress in TNBC (i.e., revealing
the identity of either the BCC-secreted factor responsible for educating osteoblasts or the
protective factor itself). The most effective treatment strategy for TNBC-derived bone
metastasis is likely to require simultaneous targeting of resistance mechanisms against
multiple forms of cell stress. Interestingly, MCF7 cells (ERpos) showed an enhanced level
of cell death induced by oxidative stress. This finding is in agreement with reports that
MCF7 cells (ERpos) are sensitive to oxidative stress which arises from their low endogenous
levels of some antioxidants [48], which is further compounded by estrogen signaling [49].
In addition, like the majority of breast cancers, MCF7 cells express both ER and wildtype,
functional p53, which renders MCF7 cells sensitive to cell death induced by oxidative
stress [49–51]. However, it remains to be determined whether p53 status directly influ-
ences the ability of breast cancer cells to engage in paracrine crosstalk with osteoblasts.
Nevertheless, our data demonstrate that the sensitivity of MCF7 cells to oxidative stress in
co-culture, and possibly in vivo, arises from their inability to secrete the paracrine media-
tors necessary for eliciting the support of osteoblasts. Taken together, these data highlight
a potential therapeutic vulnerability in ERpos bone metastasis that might be exploitable in
a clinical setting.
We observed that between 70–80% of DTCs in bone were associated with the microvas-
culature, regardless of their subsequent fate. These data are consistent with the established
importance of the perivascular niche in bone metastasis [3,7–9]. However, our data also
showed that a significant number of these perivascular DTCs were simultaneously asso-
ciated with the endosteal niche. This finding highlights the importance of overlapping
niches and the complex interplay between their various cellular components during breast
cancer metastasis to bone. This concept is supported by the observation that the successful
recreation of perivascular niches capable of supporting breast cancer cell dormancy in vitro
requires that endothelial cells be co-cultured with bone-derived osteoblast precursors [7,9].
A greater understanding of the cross-talk between this cell triad may shed further light on
the mechanisms promoting the survival of breast cancer cells in bone and reveal additional
avenues for therapeutic exploitation.
Regarding the bone microvasculature, type-HCD31pos vessels comprise proliferative
endothelial cells that regulate osteoblastogenesis and thereby couple the processes of angio-
genesis and osteogenesis in vivo [10]. Consequently, type-H vessels are more abundant in
young mice with ongoing skeletal development, but decline with age [10,26]. Therefore, we
speculated whether this type of vessel is associated with metastatic outgrowth. However,
DTCs associated with either type-H or -L vessels exhibited metastatic outgrowth, and
metastatic latency occurred even when up to 50% of DTCs were associated with type-H
vessels in mature mice. Taken together, these data demonstrate that the fate of DTCs in
bone, i.e., to grow or not, is not determined by their association with a specific subtype
of blood vessel. However, given their role in osteoblastogenesis, we cannot exclude the
possibility that type-H vessels may function as indirect, upstream regulators of breast
cancer cell survival in bone via their effects on osteoblastic cells.
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Finally, our transcriptomic and proteomic profiling of candidate molecules did not re-
veal any differentially expressed, biologically relevant, factors that could directly influence
the fate of DTCs, between the bone microenvironments of the outgrowth and indolence
models. However, there was increased osteoprotegerin expression at both mRNA and
protein level in the bone microenvironment of the indolence model. Osteoprotegerin is
a decoy receptor that sequesters and inactivates RANKL, thereby preventing osteoclast-
driven bone resorption, suggesting that a decline in bone turnover in mature mice may
be a cause of metastatic latency. This is consistent with our work and that of others show-
ing that increased osteoclast-driven bone resorption can trigger the growth of previously
indolent bone metastases, in pre-clinical models [17,28,39]. However, in our models we
did not detect differential expression of growth factors commonly sequestered in bone
(e.g., Igf, Pdgf, Fgf or Tgfb1), which may drive metastatic outgrowth if released during
bone turnover. These data suggest that the ability to grow and form overt bone metastases
might be an intrinsic property that is restricted to specific DTC clones, rather than being
determined directly and solely by the niche, which is supported by our mathematical
modelling. Indeed, the modelling suggests that the endogenous factors (i.e., metabolites
or immune-mediated phenomenon) within the bone niche may only make a minor contri-
bution to the outgrowth of DTCs. We postulate that the decline in osteoblastic cells in the
indolence model reduces the total number of DTCs that can survive in bone, thus reducing
the likelihood of an outgrowth competent clone finding a supportive niche. These data are
entirely consistent with work from the Massague [27] and Kang [28] labs, demonstrating
that only specific cancer cell clones possess the ability to drive osteoclast-mediated bone
resorption and thereby fuel metastatic outgrowth. Taken together, our study identifies a
novel process by which osteoblasts might act as upstream regulators of metastatic latency
in bone. By protecting DTCs against the mediators of metastasis-associated cell stress,
osteoblasts determine the number of supportive niches in bone available for colonization by
cancer cell clones competent of metastatic outgrowth. While additional work is required to
identify the paracrine mediator(s) that specifically protect MDA-MB-231 (TNBC) cells from
oxidative stress, gap junctional (juxtacrine) signaling represents a protective mechanism de-
ployed by both TNBC and ERpos subtypes of breast cancer. Further comprehensive in vitro
and in vivo studies are required to identify the protective pro-survival factors transferred
by gap junctions and the precise connexin proteins involved. Our novel data suggest that
the potential of combining gap junction inhibitors with current standard of care should be
explored in preclinical studies as a novel therapeutic approach for the adjuvant treatment
of breast cancer.
4. Materials and Methods
4.1. Animal Experiments
All animal experiments were conducted with the approval of the University of
Sheffield Project Applications and Amendments (Ethics) Committee and in accordance
with UK Home Office Regulations (PPL70/8964 to N.J.B.). BALB/c Nude [Foxn1-Crl]
immunodeficient mice (Charles River Laboratories, Wilmington, MA, USA) were housed
in individual ventilated cages with 12-h light/dark cycles at 22 ◦C and access to food
and water ad libitum. Experimental bone metastases were established by intra-cardiac
injection of 1 × 105 MDA-MB-231 cells, as described previously [17,18]. Mice were culled
six days post-injection for analysis before metastatic outgrowth occurs [18]. Ovariectomy
was performed as described previously [17]. One week after removal of the ovaries, or
sham operation, experimental bone metastases were established, and the mice were culled
six days post-injection.
4.2. Cell Lines and Tissue Culture, Reagents
Breast cancer cell lines MDA-MB-231GFP and MCF7 (ATCC) were cultured in RPMI-
1640 medium (Thermo Fisher Scientific, Waltham, MA, USA) containing 10% FCS. Mouse
pre-osteoblastic cell line MC3T3-E1 (ECACC) was cultured in αMEM medium (Thermo
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Fisher Scientific) containing ribonucleosides, deoxyribonucleosides and 10% FCS. To gener-
ate mature osteoblasts, MC3T3-E1 cells were differentiated for 3 weeks in αMEM containing
2mM β-glycerophosphate, 50 µg/mL ascorbate and 10% FCS. All cell lines were passaged
at 80% confluence. Details of the reagents used are included in Supplementary Table S2.
4.3. Immunofluorescent Analysis
Gelatin-embedded hind limb cryo-sections were labeled as described previously [26].
Briefly, cryo-sections were blocked with a streptavidin/biotin blocking kit (Vector Laborato-
ries, Birlingame, CA, USA), incubated for 1.5–2 h with directly conjugated or unconjugated
primary antibodies (2 µg/mL) followed by 1 h with either biotinylated (7.5 µg/mL) or
fluorescent (5 µg/mL) secondary antibodies. Where appropriate, slides were incubated
for 20 min with fluorescently conjugated streptavidin (10 µg/mL). Labelled sections were
stained with DAPI and mounted in ProLong Diamond Antifade (Thermo Fisher Scientific,
Waltham, MA, USA). Primary antibodies were directed against mouse Endomucin (Santa
Cruz Biotechnology, Dallas, TX, USA), CD31 (Dianova, New York, NY, USA), Osteopontin
(RandD Systems, Minneapolis, MN, USA), Osterix (Abcam, Cambridge, MA, USA) and
human CD29 and CD59 (BioLegend, San Diego, CA, USA). Image were acquired using
a Nikon A1 confocal microscopy (Nikon, Tokyo, Japan) and the images were analyzed
using ImageJ (National Institutes of Health [NIH], Bethesda, MD, USA). To determine the
abundance of osteoprogenitors in proximity to DTCs (‘Hotspot analysis’) high powered
fields (HPF) of view were acquired using a 40× oil immersion objective lens. Each HPF
was centered on the DTCs and the numbers of osteoprogenitors present was quantified.
4.4. Oxidative Stress and Serum Deprivation Assays
For both assays, MC3T3-E1 cells were grown to confluence in 12-well plates. For
oxidative stress assays, BCCs (5 × 104 cells/well) were seed onto confluent MC3T3-E1s and
24 h later co-cultures were treated with 400 µM H2O2. BCC viability was determined 24 h
post-treatment by flow cytometry by addition of the cell impermeant DNA-binding dye
TO-PRO-3TM, which labels the nuclei of dead cells [52,53]. For serum-starvation assays,
BCCs were seeded directly onto confluent MC3T3-E1s in serum-free αMEM at a density
of 1 × 105/well and incubated for 48 h and tumor cell viability was determined by flow
cytometry. To generate conditioned medium, confluent monolayers of MC3T3-E1 cells were
cultured alone and in combination with 1 × 105 BCCs in either full serum or serum-free
αMEM for 48 h. GSH was depleted from co-culture conditioned medium using the γ-
Glutamylcysteine synthase inhibitor ”Buthionine Sulfoximine” (BSO—100µM). Co-cultures
were treated with BSO for 24 h, the medium was then replaced, and conditioned medium
collected overnight in the absence of BSO. Gap junction, notch and integrin-mediated
signaling pathways were inhibited in co-cultures using Carbenoxolone (25–50 µM), the
γ-secretase inhibitor ”DAPT” (1 µM) and integrin-neutralizing antibodies (10–50 µg/mL),
respectively. Inhibitors were added to co-culture assays at the time of tumor cell seeding.
Each test condition was measured in triplicate in three independent experiments.
4.5. Protein Array and ELISA
Protein lysates were generated from snap-frozen femurs as described previously [26].
Mouse ”Growth Factor Array C3“, ”Angiogenesis Array C1“ and ”Cytokine Array C1000“
(RayBiotech, Peachtree Corners, GA, USA) were incubated with 1 mg of total protein
pooled from four mice (250 µg protein/mouse) aged 6-week and 12-week. Membranes
were developed using a chemiluminescent substrate and GelDoc imaging system (BioRad
Laboratories, Hercules, CA, USA). Densitometric analysis or protein expression was per-
formed using ImageJ software (National Institutes of Health [NIH], Bethesda, MD, USA).
Changes in expression ~50% were deemed biologically relevant. Colorimetric ELISAs for
mouse Cxcl4 (Abcam, Cambridge, MA, USA), Cxcl11 and Cxcl15 (RayBiotech, Peachtree
Corners, GA, USA), Collagen IV (Bio-techne, Minneapolis, MN, USA), and FasL (Cam-
bridge Bioscience, Cambridge, UK) were conducted using protein lysates from 4 individual
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mice aged 6-week and 12-week-old, samples from each mouse were measured in triplicate,
after first adjusting the total protein concentration of each sample to 4 mg/mL by dilution
with PBS.
4.6. Gap Junction-Mediated Transfer of Calcein
MC3T3-E1 cells were suspended in PBS containing calcein-AM (1 µM) for 20 min
at 37 ◦C, washed thoroughly with PBS and seeded at a 1:1 ratio with MDA-MB-231
(5 × 104 cells/well) in αMEM for 24 h. Calcein transfer was imaged using a Nikon A1
confocal microscope.
4.7. Real-Time Quantitative PCR
RNA was extracted from marrow and bone-lining cells from mouse tibias as described
previously [26] and 1 µg of total RNA reverse transcribed using a QuantiTect Reverse
Transcription Kit (Qiagen, Hilden, Germany). Gene expression was determined using
in-house validated SYBR green primers (sequences specified in Supplementary Table
S1) and an HT7900 real-time PCR instrument (Thermo Fisher Scientific). Changes in
gene expression were calculated using a relative quantification approach (∆∆Ct) after
first normalizing to the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (Table S1). Experiments were performed using four mice in each treatment
group. The expression of each gene of interest was measured in triplicate for each mouse
(n = 4).
4.8. Mathematical Modelling of Outgrowth Probability
The birth and death of cancer cells was modelled as a continuous time Markov chain
using a discrete random variable N(t) number of DTCs at time t and constant birth and
death rate parameters such that the birth and death rates are linearly proportional to the
population number N. We solved the differential equation using a probability generation
function to find the extinction probability at long times, P(tumor) = 1 − An, where A is the
ratio of death rate to proliferation rate and n is the initial number of DTCs (see Figure S2
for further details).
4.9. Statistical Analysis
Statistical analyses were performed using Prism software (v.8.0; GraphPad Software,
Irvine, CA, USA). All data are presented as sample means ± SEM and all data were
analyzed by one- or two-tailed student’s t-test, or one-way ANOVA, where appropriate. A
statistically significant difference was defined as p < 0.05.
5. Conclusions
Our study deployed a range of molecular, cellular and in vivo methodologies to
generate compelling evidence that osteoblasts act as regulators of metastatic outgrowth in
bone by dictating the overall abundance of DTCs. Osteoblasts were found to deploy a range
of paracrine and juxtacrine mechanism that protect DTCs from death induced by mediators
of metastasis-induced cell stress, with gap junctional signaling being of particular interest.
In addition to the established role for heterotypic gap junction signaling in promoting
the proliferation of ERpos DTCs in pre-clinical mouse models, we now extend this work
by demonstrating their role as conveyors of osteoblast-derived cues that promote breast
cancer cell resistance to cell stress. Taken together, our data indicate that targeting the
interaction between DTCs and osteoblasts, particularly gap junctional signaling, could be
explored as a therapeutic approach to eliminate minimal residual disease.
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